The trail aimed to test the efficacy of AI-based rehabilitation treatment in patients with anxiety disorders. Specifically, the objective of this trial is to determine whether the AI-based rehabilitation combined with treatment as usual is more effective than treatment as usual alone in improving outcomes in patients with anxiety disorders.
In accordance with ICD-11 for Anxiety Disorders;
Between the ages of 18-60;
Completed at least 9 years of education;
Ability to use computers or smartphone;
With severe psychiatric symptoms requiring hospitalization, or unable to complete the required assessment and treatment;
Use of cognitive-enhancing medications within the past 6 months;
With intellectual, visual, or auditory impairments that affect their ability to interact with aided-diagnostic systems.
Parallel
AI-based rehabilitation treatment combined with standard treatment
DeviceParticipants were offered a 3-week psychological intervention , delivered by the AI-based rehabilitation system. The system contains 12 core topics, such as basic knowledge and emotion regulation, cognitive restructuring, behavior activation, interpersonal communication skills, mindfulness and sleep, and relaxation training. The intervention schedule was 4 sessions per week, each lasting approximately 20 minutes, for a total of 12 sessions.
Treatment as Usual (TAU)
Other interventionBoth groups will receive treatment as usual, including medication, exercise and psychological education.
Change from baseline in anxiety symptoms, as measured by the Generalized Anxiety Disorder 7-item Scale (GAD-7)
Change in anxiety symptoms, measured by reduction in total score and rate of score reduction on the Generalized Anxiety Disorder 7-item Scale (GAD-7). The GAD-7 total score ranges from 0 to 21, with higher scores indicating greater severity of anxiety symptoms.
Change from baseline in depression status, as assessed by the Patient Health Questionnaire-9 (PHQ-9).
Change in depressive symptoms, measured by reduction in total score and rate of score reduction on the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 total score ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Change from baseline in social anxiety symptoms, as measured by the Liebowitz Social Anxiety Scale (LSAS).
Change in social anxiety symptoms, measured by reduction in total score and rate of score reduction on the Liebowitz Social Anxiety Scale (LSAS). The LSAS total score ranges from 0 to 144, with higher scores indicating greater severity of social anxiety symptoms.
Change from baseline in emotion regulation ability, as measured by the Emotion Regulation Questionnaire (ERQ).
Change in emotion regulation ability, measured by total score on the Emotion Regulation Questionnaire (ERQ). The ERQ total score ranges from 0 to 70, with higher scores indicating greater use of emotion regulation strategies and better emotion regulation ability.
Change from baseline in resilience level, as assessed by the Connor-Davidson Resilience Scale-10 (CD-RISC-10).
Change in resilience level, measured by total score on the Connor-Davidson Resilience Scale-10 (CD-RISC-10). The CD-RISC-10 total score ranges from 0 to 40, with higher scores indicating greater psychological resilience.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
